<DOC>
	<DOC>NCT00915278</DOC>
	<brief_summary>Dose finding study of the MoaB PF-04605412 directed against the alpha5beta1 integrin. Main objective is to define the MTD (maximum tolerated dose) or MAD (maximum administrable dose) in cancer patients pre treated or unresponsive to standard therapies.</brief_summary>
	<brief_title>A Safety Study Of A Monoclonal Antibody Against A5B1 Integrin In Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Histologically or cytologically confirmed advanced measurable or evaluable solid tumors unresponsive to currently available therapies, or for which there is no curative therapy Eastern Cooperative Oncology Group (ECOG) performance status 0 and 1 Life expectancy more than12 weeks Adequate bone marrow, liver and renal function Known brain metastasis Chemotherapy, radiotherapy, or any investigational cancer therapy within 4 weeks of start of screening procedures Major surgical procedure within 4 weeks of start of screening procedures Active bleeding disorder, including gastrointestinal bleeding, as evidenced by hematemesis, significant hemoptysis or melena in the past 6 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Neoplasms</keyword>
	<keyword>monoclonal antibody</keyword>
	<keyword>PF-04605412</keyword>
	<keyword>advanced metastatic solid tumors</keyword>
</DOC>